Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term K_M and K_erg potassium channels refers to two distinct classes of voltage-gated potassium channels that are fundamental to the electrical activity of the nervous system and the heart. K_M channels, primarily encoded by the KCNQ (Kv7) gene family (specifically KCNQ2, KCNQ3, KCNQ4, and KCNQ5), generate the M-current, a slow-activating and non-inactivating current that regulates the resting membrane potential and controls neuronal firing frequency [1, 2]. Mutations in KCNQ genes are linked to conditions such as Benign Familial Neonatal Seizures (BFNS) and early-onset encephalopathy, making them significant targets for anti-epileptic drugs like retigabine, which act as channel openers to reduce hyperexcitability [2]. In contrast, K_erg channels, specifically the human Ether-à-go-go-Related Gene (hERG or KCNH2), are responsible for the rapid delayed rectifier potassium current (I_Kr) in the heart, which is essential for the repolarization phase of the cardiac action potential [3, 4]. While hERG is a target for certain Class III anti-arrhythmic drugs like dofetilide, it is most notorious in pharmacology for its sensitivity to unintended blockade by a wide variety of non-cardiac medications [4]. Such off-target inhibition can lead to acquired Long QT Syndrome and potentially fatal arrhythmias like Torsades de Pointes, necessitating rigorous hERG safety screening for all new drug candidates [3]. Together, these channels represent critical checkpoints for maintaining physiological rhythmicity and are central to both therapeutic intervention and drug safety assessment. [1] Wang, H. S., et al. (1998). Science. [2] Delmas, P., & Brown, D. A. (2005). Nature Reviews Neuroscience. [3] Sanguinetti, M. C., & Tristani-Firouzi, M. (2006). Nature. [4] Vandenberg, J. I., et al. (2012). Physiological Reviews.
K_M channels are targeted by positive allosteric modulators (openers) to stabilize the membrane potential and suppress neuronal over-activity. K_erg channels are targeted by blockers to prolong the cardiac action potential duration in anti-arrhythmic therapy, though they are more frequently the site of unintended drug-induced blockade leading to cardiotoxicity.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on M-type and Ether-à-go-go-related gene potassium channels (K_M and K_erg).